Follow
Forugh Sanaee
Forugh Sanaee
Pharmacist
Verified email at ualberta.ca
Title
Cited by
Cited by
Year
Drug− disease interaction: Crohn's disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity
F Sanaee, JD Clements, AWG Waugh, RN Fedorak, R Lewanczuk, ...
British journal of clinical pharmacology 72 (5), 787-797, 2011
362011
Decoration of anti-CD38 on nanoparticles carrying a STAT3 inhibitor can improve the therapeutic efficacy against myeloma
YH Huang, MR Vakili, O Molavi, Y Morrissey, C Wu, I Paiva, AH Soleimani, ...
Cancers 11 (2), 248, 2019
312019
NSAIDs do not require the presence of a carboxylic acid to exert their anti-inflammatory effect–why do we keep using it?
N Ullah, Z Huang, F Sanaee, A Rodriguez-Dimitrescu, F Aldawsari, ...
Journal of enzyme inhibition and medicinal chemistry 31 (6), 1018-1028, 2016
292016
Development and pharmacokinetic evaluation of a self-nanoemulsifying drug delivery system for the oral delivery of cannabidiol
LY Kok, P Bannigan, F Sanaee, JC Evans, M Dunne, M Regenold, ...
European Journal of Pharmaceutical Sciences 168, 106058, 2022
232022
A synthetically lethal nanomedicine delivering novel inhibitors of polynucleotide kinase 3′-phosphatase (PNKP) for targeted therapy of PTEN-deficient colorectal cancer
SMA Sadat, IM Paiva, Z Shire, F Sanaee, TDR Morgan, M Paladino, ...
Journal of Controlled Release 334, 335-352, 2021
122021
Pharmacokinetics of nebivolol in the rat: low oral absorption, loss in the gut and systemic stereoselectivity
F Sanaee, D Valente Neves, VL Lanchote, F Jamali
Biopharmaceutics & drug disposition 34 (6), 312-320, 2013
112013
Action and disposition of the β3-agonist nebivolol in the presence of inflammation; an alternative to conventional β1-blockers
F Sanaee, F Jamali
Current Pharmaceutical Design 20 (9), 1311-1317, 2014
62014
Nano-delivery of a novel inhibitor of polynucleotide kinase/phosphatase (PNKP) for targeted sensitization of colorectal cancer to radiation-induced DNA damage
SMA Sadat, M Wuest, IM Paiva, S Munira, N Sarrami, F Sanaee, X Yang, ...
Frontiers in Oncology 11, 772920, 2021
52021
Design and evaluation of albumin nanoparticles for the delivery of a novel β-tubulin polymerization inhibitor
A Spada, J Emami, F Sanaee, M Aminpour, MP Igor, J Tuszynski, ...
Journal of Pharmacy & Pharmaceutical Sciences 24, 344-362, 2021
52021
Assessing the physicochemical stability of a compounded neonatal trace element solution
F Sanaee, T Mysak, L Sanderson, T Donaldson, MR Vakili, A Lavasanifar
Journal of Pharmacy & Pharmaceutical Sciences 21 (1s), 103s-116s, 2018
22018
Effects of Inflammation and the Severity of Disease on the Action and Disposition of Drugs
F Sanaee
University of Alberta (Canada), 2014
12014
Abstract P2103: Cannabidiol Protects Cardiac Function In Vivo And Inhibits Endothelial-to-mesenchymal Transition In Vitro: A Potential Anti-fibrotic Therapy For …
MK Krishnamoorthi, F Sanaee, A Lavasanifar, K Youker, A Bhimaraj
Circulation Research 131 (Suppl_1), AP2103-AP2103, 2022
2022
Cannabidiol Loaded Nanoparticles Exhibit an Anti-Fibrotic Effect in a Mouse Model of Non-Ischemic Heart Failure
MK Krishnamoorthi, F Sanaee, A Lavasanifar, A Bolton, K Youker, ...
Circulation 144 (Suppl_1), A10708-A10708, 2021
2021
DISEASE-DRUG INTERACTION: REDUCES RESPONSE TO CALCIUM CHANNEL BLOCKER VERAPAMIL DESPITE INCREASED CONCENTRATION IN ACTIVE CROHN'S DISEASE
F Sanaee, JD Clements, A Waugh, R Fedorak, RZ Lewanczuk, F Jamali
CANADIAN JOURNAL OF CARDIOLOGY 26, 56D-57D, 2010
2010
DISEASE-DRUG INTERACTION: REDUCES RESPONSE TO VERAPAML DESPITE INCREASED CONCENTRATION IN ACTIVE CROHN'S DISEASE.
F Sanaee, JD Clements, A Waugh, R Fedorak, R Lewanczuk, F Jamali
JOURNAL OF CLINICAL PHARMACOLOGY 49 (9), 1124-1124, 2009
2009
The system can't perform the operation now. Try again later.
Articles 1–15